COMPANY

Cel-Sci Corporation

HQ: Vienna, VA source · cel-sci.com ↗ · Southeast

Location: Vienna, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: rheumatoid arthritis herpes simplex Perianal Warts Squamous Cell Carcinoma of the Oral Cavity Squamous Cell Carcinoma of the Soft Palate autoimmune myocarditis

2Trials (company is sponsor)9NIH grants

Timeline

2015-04 Trial start Phase 1: Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts source ↗
2010-12 Trial start Phase 3: Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT03038828	Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts	Phase 1	Terminated	2015-04	2018-06 (actual)
NCT01265849	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity	Phase 3	Completed	2010-12	May 15, 2020 (actual)

NIH awards 9

Annual award amounts. Total $3.0M.

Aug 8, 2018 NIH award 5R44AR063504-03 FY2018: $691,469 awarded for that fiscal year; activity R44 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. Preclinical studies of PG70 LEAPS peptid source ↗
Sep 15, 2017 NIH award 2R44AR063504-02A1 FY2017: $806,505 awarded for that fiscal year; activity R44 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. Preclinical studies of PG70 LEAPS pept source ↗
Jul 14, 2014 NIH award 1R43AR063504-01A1 FY2014: $224,999 awarded for that fiscal year; activity R43 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. Preclinical Studies of PG70 LEAPS Pept source ↗
Sep 29, 2003 NIH award 1R43AI052951-01A1 FY2003: $104,091 awarded for that fiscal year; activity R43 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. Augmenting innate and vaccine immune r source ↗
2003 NIH award 1R43AI055069-01 FY2003: $162,132 awarded for that fiscal year; activity R43 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. derG Immunostimulant Prevention/Treatmen source ↗
2003 NIH award 1R43HL071352-01A1 FY2003: $134,469 awarded for that fiscal year; activity R43 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. Peptide Vaccine for Experimental Autoi source ↗
Sep 3, 2001 NIH award 5R44AI043107-03 FY2001: $385,063 awarded for that fiscal year; activity R44 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. HETEROCONJUGATE VACCINES AGAINST HERPES source ↗
Sep 29, 2000 NIH award 2R44AI043107-02A1 FY2000: $379,053 awarded for that fiscal year; activity R44 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. HETEROCONJUGATE VACCINES AGAINST HERPE source ↗
May 22, 1998 NIH award 1R43AI043107-01 FY1998: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI ZIMMERMAN, DANIEL HILL; recipient as written: CEL-SCI CORPORATION, VIENNA, VA. HETEROCONJUGATE VACCINES AGAINST HERPES source ↗